65 related articles for article (PubMed ID: 30284405)
1. Clinical performance of the Cobas 4800 HPV test and the Aptima HPV assay in the management of women referred to colposcopy with minor cytological abnormalities.
Tewari P; White C; Kelly L; Pilkington L; Keegan H; D'Arcy T; Toole SO; Sharp L; O'Leary JJ; Martin CM
Diagn Cytopathol; 2018 Dec; 46(12):987-992. PubMed ID: 30284405
[TBL] [Abstract][Full Text] [Related]
2. Comparison of human papillomavirus detection by Aptima HPV and cobas HPV tests in a population of women referred for colposcopy following detection of atypical squamous cells of undetermined significance by Pap cytology.
Castle PE; Eaton B; Reid J; Getman D; Dockter J
J Clin Microbiol; 2015 Apr; 53(4):1277-81. PubMed ID: 25653409
[TBL] [Abstract][Full Text] [Related]
3. Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above.
Rebolj M; Bonde J; Preisler S; Ejegod D; Rygaard C; Lynge E
PLoS One; 2016; 11(1):e0147326. PubMed ID: 26789267
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the Clinical Performance of Aptima HPV Assay and the Cobas 4800 Platform in Women with Normal Cytology and Positive High-Risk HPV.
Kir G; Dokmeci Guney D; Seneldir H
Acta Cytol; 2023; 67(4):395-402. PubMed ID: 36977394
[TBL] [Abstract][Full Text] [Related]
5. Aptima HPV Assay versus Hybrid Capture
Cook DA; Smith LW; Law J; Mei W; van Niekerk DJ; Ceballos K; Gondara L; Franco EL; Coldman AJ; Ogilvie GS; Jang D; Chernesky M; Krajden M
J Clin Virol; 2017 Feb; 87():23-29. PubMed ID: 27988420
[TBL] [Abstract][Full Text] [Related]
6. Clinical performance of RNA and DNA based HPV testing in a colposcopy setting: Influence of assay target, cut off and age.
Cuschieri K; Cubie H; Graham C; Rowan J; Hardie A; Horne A; Earle CB; Bailey A; Crosbie EJ; Kitchener H
J Clin Virol; 2014 Feb; 59(2):104-8. PubMed ID: 24380720
[TBL] [Abstract][Full Text] [Related]
7. Comparison of three human papillomavirus DNA assays and one mRNA assay in women with abnormal cytology.
Rebolj M; Lynge E; Ejegod D; Preisler S; Rygaard C; Bonde J
Gynecol Oncol; 2014 Dec; 135(3):474-80. PubMed ID: 25449563
[TBL] [Abstract][Full Text] [Related]
8. HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer.
Ogilvie GS; Krajden M; van Niekerk D; Smith LW; Cook D; Ceballos K; Lee M; Gentile L; Gondara L; Elwood-Martin R; Peacock S; Stuart G; Franco EL; Coldman AJ
Int J Cancer; 2017 Jan; 140(2):440-448. PubMed ID: 27685757
[TBL] [Abstract][Full Text] [Related]
9. A daunting challenge: Human Papillomavirus assays and cytology in primary cervical screening of women below age 30years.
Rebolj M; Bonde J; Ejegod D; Preisler S; Rygaard C; Lynge E
Eur J Cancer; 2015 Jul; 51(11):1456-66. PubMed ID: 25979832
[TBL] [Abstract][Full Text] [Related]
10. The reliability of high-risk human papillomavirus detection by Aptima HPV assay in women with ASC-US cytology.
Castle PE; Reid J; Dockter J; Getman D
J Clin Virol; 2015 Aug; 69():52-5. PubMed ID: 26209379
[TBL] [Abstract][Full Text] [Related]
11. Clinical evaluation of human papillomavirus 16/18 oncoprotein test for cervical cancer screening and HPV positive women triage.
Yu L; Jiang M; Qu P; Wu Z; Sun P; Xi M; Qin Y; Liu X; Liao G; Lei X; Sun L; Zhang Y; Li Z; Chen W; Qiao YL
Int J Cancer; 2018 Aug; 143(4):813-822. PubMed ID: 29524206
[TBL] [Abstract][Full Text] [Related]
12. Clinical performance and acceptability of self-collected vaginal and urine samples compared with clinician-taken cervical samples for HPV testing among women referred for colposcopy. A cross-sectional study.
Ørnskov D; Jochumsen K; Steiner PH; Grunnet IM; Lykkebo AW; Waldstrøm M
BMJ Open; 2021 Mar; 11(3):e041512. PubMed ID: 33674367
[TBL] [Abstract][Full Text] [Related]
13. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
14. Transition from Hybrid Capture 2 to Cobas 4800 in Hpv detection: sensitivity and specificity for Cin2+ in two time periods.
Bottari F; Boveri S; Iacobone AD; Gulmini C; Igidbashian S; Cassatella MC; Landoni F; Sandri MT
Infect Dis (Lond); 2018 Jul; 50(7):554-559. PubMed ID: 29463149
[TBL] [Abstract][Full Text] [Related]
15. Detection of cervical precancerous lesions with Aptima HPV assays using SurePath preservative fluid specimens.
Chernesky M; Jang D; Escott N; Gilchrist J; Li J; Elit L; Lytwyn A; Smieja M; Ratnam S; Arias M; Getman D; Weinbaum B; Kirkconnell B; Dockter J
Papillomavirus Res; 2017 Jun; 3():155-159. PubMed ID: 28720450
[TBL] [Abstract][Full Text] [Related]
16. The Aptima HPV assay fulfills the cross-sectional clinical and reproducibility criteria of international guidelines for human papillomavirus test requirements for cervical screening.
Heideman DA; Hesselink AT; van Kemenade FJ; Iftner T; Berkhof J; Topal F; Agard D; Meijer CJ; Snijders PJ
J Clin Microbiol; 2013 Nov; 51(11):3653-7. PubMed ID: 23985912
[TBL] [Abstract][Full Text] [Related]
17. Performance of the HPV E6/E7 mRNA Aptima HPV assay combined with partial genotyping compared with the HPV DNA Cobas 4800 HPV test for use in primary screening: Results from the CERVIVA HPV primary screening study in Ireland.
White C; Reynolds S; Murphy K; Keegan H; Naik P; O'Brien R; Pilkington L; Sharkey Ochoa I; Glesson G; Russell N; Nuttall D; Tewari P; Wright F; O'Toole S; Sharp L; Flannelly G; O'Leary JJ; Martin CM;
Int J Cancer; 2024 Jan; 154(1):53-64. PubMed ID: 37632406
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study.
Monsonego J; Hudgens MG; Zerat L; Zerat JC; Syrjänen K; Halfon P; Ruiz F; Smith JS
Int J Cancer; 2011 Aug; 129(3):691-701. PubMed ID: 20941740
[TBL] [Abstract][Full Text] [Related]
19. Comparative cost analysis of cervical cancer screening programme based on molecular detection of HPV in Spain.
Ibáñez R; Mareque M; Granados R; Andía D; García-Rojo M; Quílez JC; Oyagüez I
BMC Womens Health; 2021 Apr; 21(1):178. PubMed ID: 33902553
[TBL] [Abstract][Full Text] [Related]
20. Testing of integrated human papillomavirus mRNA decreases colposcopy referrals: could a change in human papillomavirus detection methodology lead to more cost-effective patient care?
Sauter JL; Mount SL; St John TL; Wojewoda CM; Bryant RJ; Leiman G
Acta Cytol; 2014; 58(2):162-6. PubMed ID: 24526177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
